이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Comparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema

2026년 11월 10일 업데이트: Halic University

This randomized crossover clinical trial aims to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will receive both treatment approaches in different sequences. Each intervention period will last 4 weeks, with a 2-week washout period between treatments. Manual lymphatic drainage will be applied three times per week during the intervention periods. Assessments will be performed at baseline, week 4, and week 10.

연구 개요

상태

초대로 등록

정황

개입 / 치료

상세 설명

This randomized crossover clinical trial was designed to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will be randomly allocated to one of two treatment sequences. In the first 4-week treatment period, one group will receive Kinesio Taping combined with manual lymphatic drainage, while the other group will receive compression bandaging combined with manual lymphatic drainage. Manual lymphatic drainage will be administered three times per week during the intervention periods.

After completion of the first 4-week treatment period, a 2-week washout period will be implemented. Following the washout period, participants will cross over to the alternative intervention for an additional 4 weeks. Participants who initially received Kinesio Taping will subsequently receive compression bandaging, whereas participants who initially received compression bandaging will subsequently receive Kinesio Taping.

Clinical assessments will be performed at baseline, at the end of the first treatment period (week 4), and at the end of the second treatment period (week 10). Upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength will be evaluated at these time points.

The crossover design allows all participants to receive both therapeutic interventions and enables within-participant comparison of the effects of Kinesio Taping and compression bandaging. The 2-week washout period is included to reduce potential carryover effects from the first treatment period before initiation of the second intervention.

연구 유형

중재적

등록 (추정된)

44

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Bakırköy
      • Istanbul, Bakırköy, 터키 (Türkiye), 34149
        • Istanbul University Cerrahpaşa Faculty of Medicine Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Diagnosis of lymphedema following breast cancer treatment (confirmed by clinical evaluation or objective measurements).
  • Age between 18 and 75 years (adult participants will be included).
  • Willingness to participate voluntarily in the study and provision of written informed consent.
  • Unilateral lymphedema (to ensure standardization of assessments).
  • Lymphedema in the chronic stage (present for more than 3 months).
  • A stable condition in terms of lymphedema treatment (no other lymphedema treatment received within the last month).
  • Sufficient functional capacity to complete physical assessments and measurements (movement limitations should not be at a level that prevents evaluation).

Exclusion Criteria:

  • History of advanced-stage cancer or active metastatic disease.
  • Presence of severe cardiovascular or respiratory disease (e.g., heart failure, chronic obstructive pulmonary disease).
  • History of diabetic neuropathy or peripheral vascular disease (may affect lymphedema management due to circulatory impairment).
  • Presence of severe skin reactions or dermatological conditions (that compromise skin integrity and prevent tape application).
  • Pregnancy or breastfeeding.
  • History of allergic reactions to kinesio tape or compression bandages.
  • History of lymphatic drainage surgery or other surgical intervention within the past 6 months.
  • Diagnosis of bilateral lymphedema (only unilateral cases will be included to standardize the assessment process).
  • Inability to actively participate in the study due to mental or cognitive impairment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Kinesiotaping Group

Patients with lymphedema who will receive kinesio taping treatment first, followed by compression bandaging.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

실험적: Compression Bandaging

Patients with lymphedema who will receive compression bandaging first, followed by kinesio taping treatment.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Upper Extremity Edema
기간: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Arm circumference measurement was used as an objective indicator of lymphedema severity. Circumferential measurements were obtained using a non-elastic tape measure at standardized anatomical landmarks along the upper extremity. Measurements were taken at fixed intervals (e.g., every 5 cm) starting from the wrist and progressing proximally toward the elbow and upper arm.

Values were recorded in millimeters (mm), with higher circumference values indicating greater edema severity. There is no predefined upper limit for arm circumference; therefore, larger measurements reflect increased fluid accumulation, whereas smaller values indicate reduced edema.

To quantify lymphedema, the difference in circumference between the affected and unaffected extremities was calculated at each measurement point. A greater inter-limb difference represents more severe lymphedema, while a reduction in this difference over time indicates clinical improvement.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Pain Intensity
기간: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

The Visual Analog Scale (VAS) is a 10-centimeter horizontal line used to assess pain intensity. Scores range from 0 to 10, where 0 indicates no pain and 10 indicates worst imaginable pain. Higher scores indicate greater pain severity.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Shoulder Range of Motion
기간: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Joint range of motion (ROM) was assessed to evaluate upper-extremity mobility in individuals with lymphedema. Active ROM measurements were obtained using a standard universal goniometer based on anatomical landmarks. Measurements were recorded in degrees (°) for wrist, elbow, forearm, and shoulder movements.

Higher ROM values indicate greater joint mobility and better functional status, whereas lower values reflect movement limitation. As ROM does not have a single fixed maximum value, results were interpreted relative to anatomical normative values and the contralateral limb.

A reduction of ≥10° compared with the unaffected side was considered a clinically meaningful limitation, while an increase toward normal values over time was interpreted as a positive treatment response. Each movement was measured three times, and the mean value was used for analysis. ROM assessments were performed at baseline and after each intervention period.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Upper Extremity Function
기간: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Upper-extremity functioning was assessed using the Disabilities of the Arm, Shoulder and Hand (QuickDASH) Functioning Scale, a self-reported questionnaire designed to evaluate physical function and symptoms related to upper-limb disorders. The QuickDASH consists of 30 items, each scored on a 5-point Likert scale ranging from 1 (no difficulty) to 5 (unable to perform or extreme difficulty).

Item scores are combined and transformed into a total score ranging from 0 to 100, where 0 indicates no disability and 100 represents the most severe functional limitation. Higher scores therefore reflect worse upper-extremity functioning and greater disability.

A decrease in QuickDASH score over time indicates functional improvement, whereas an increase reflects worsening functional status. The QuickDASH has no absolute clinical cut-off; however, changes of 10-15 points are generally considered clinically meaningful.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Grip Strength
기간: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Grip strength was assessed using a Jamar hand dynamometer, a widely accepted and reliable instrument for measuring isometric hand grip strength in clinical and research settings. Measurements were recorded in kilograms (kg), with higher values indicating greater muscle strength and better functional capacity, and lower values reflecting reduced grip strength.

Participants were seated in a standardized position with the shoulder adducted and neutrally rotated, the elbow flexed at 90 degrees, the forearm in a neutral position, and the wrist positioned between 0-30° extension and 0-15° ulnar deviation. Participants were instructed to squeeze the dynamometer with maximal effort for a few seconds. Each hand was tested three times, with adequate rest between trials to minimize fatigue, and the mean value was used for analysis.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Seda Yildiz, PhD, Halic University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 2월 8일

기본 완료 (추정된)

2027년 1월 1일

연구 완료 (추정된)

2027년 4월 1일

연구 등록 날짜

최초 제출

2026년 2월 23일

QC 기준을 충족하는 최초 제출

2026년 11월 2일

처음 게시됨 (실제)

2026년 11월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 2월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 400

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All data obtained from the assessment scales used in the study will be shared; however, patients' personal information, including names, surnames, and contact details, will be kept confidential. These personal data will only be shared on an individual basis if specifically requested.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .